ArticleCell2008
Silencing HIV-1 In Vivo.
Article in Cell, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Topoisomerase II β Gene Specific siRNA Delivery by Nanoparticles Prepared with c-ter Apotransferrin and its Effect on HIV-1 Replication.Molecular biotechnology · 2021Article
- The Application of Humanized Mouse Models for the Study of Human Exclusive Viruses.Methods in molecular biology (Clifton, N.J.) · 2017Article
- Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers.PloS one · 2015Article
- Article
- Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer.Nanomedicine : nanotechnology, biology, and medicine · 2013Article
- Dendronized gold nanoparticles for siRNA delivery.Small (Weinheim an der Bergstrasse, Germany) · 2012Article
- Modulation of HIV pathogenesis and T-cell signaling by HIV-1 Nef.Future virology · 2012Article
- Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis.PloS one · 2011Article
- RNA interference inhibits hepatitis E virus mRNA accumulation and protein synthesis in vitro.Veterinary microbiology · 2010Article
- RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?Expert opinion on biological therapy · 2010Review
- Strategies for targeted nonviral delivery of siRNAs in vivo.Trends in molecular medicine · 2009Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
RNA interference holds great promise for antiviral therapy, but delivering effective quantities of small interfering RNAs (siRNAs) into the right target cells in vivo represents a major challenge. Kumar et al. (2008) now report a technique to target siRNAs specifically to T cells to suppress viral infection in a humanized mouse model of HIV/AIDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.